Lantern Pharma Inc.
LTRN- 1M
- -34.7%
Lantern Pharma Inc. in brief
Lantern Pharma Inc. is a listed company in the Biotechnology industry, based in Dallas, Texas, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,645th largest listed company in the world and the 4,269th largest in the USA on this site. It employs about 16 people and Panna Sharma is its chief executive. Its shares trade under the symbol LTRN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lantern Pharma Inc.
We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program.
From the company's annual report filed with the US SEC: read the report
Lantern Pharma Inc. timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 June 2020; shares registered for exchange trading on 8 June 2020.
Events of Lantern Pharma Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,582 (Jan 2021) · #4,590 (Jan 2022) · #4,643 (Dec 2022) · #4,727 (Jul 2023) · #4,110 (Jan 2024) · #2,250 (Mar 2026) · #3,845 (Aug 2026) · #4,136 (Sep 2026) · #4,272 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.8×
- Free cash flow yield
- -135.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -262.2%
- Liabilities / assets
- 40.8%
- Profit per employee
- $-1.1 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-18M | $-17M | — |
| Dec 2024 | — | — | $-22M | $-21M | — |
| Dec 2023 | — | — | $-18M | $-16M | — |
| Dec 2022 | — | — | $-14M | $-14M | — |
| Dec 2021 | — | — | $-13M | $-12M | — |
| Dec 2020 | — | — | — | $-6M | — |
| Dec 2019 | — | — | — | $-2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-16M | $0M | $-16M | $-1.57 | — |
| Dec 2024 | $-18M | $0M | $-18M | $-1.93 | — |
| Dec 2023 | $-14M | $0M | $-14M | $-1.47 | — |
| Dec 2022 | $-13M | $0M | $-13M | $-1.31 | — |
| Dec 2021 | $-11M | $0M | $-11M | $-1.13 | — |
| Dec 2020 | $-6M | — | — | $-1.37 | — |
| Dec 2019 | $-2M | — | — | $-1.23 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 19, 2026DEF 14AProxy statement
- Oct 1, 20268-KCurrent reportListing notice
- Sep 30, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Sep 24, 20268-KCurrent reportRegulation FD disclosure
- Sep 23, 20268-KCurrent reportRegulation FD disclosure
- Aug 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportRegulation FD disclosure
- Jun 12, 2026S-1IPO registration
- Jun 2, 20268-KCurrent reportRegulation FD disclosure
- May 15, 20268-KCurrent reportResults of operations
- May 15, 202610-QQuarterly report · period to Mar 2026
Official filings of Lantern Pharma Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-18 M
- Net income
- $-17 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $11 M
- Total liabilities
- $5 M
- Total equity
- $7 M
As of December-2025
Top 43 institutional investors in Lantern Pharma Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 1,036,000 | New | 8.10% | $1 M | Nov 16, 2026 |
| 2 | Empery Asset Management, LP | 543,337 | -299,332 (-35.52%) | 4.25% | $1 M | Nov 16, 2026 |
| 3 | CM Management, LLC | 500,000 | 0 (0.00%) | 3.91% | $1 M | Nov 12, 2026 |
| 4 | Vanguard Capital Management LLC | 420,286 | -4,832 (-1.14%) | 3.29% | $0 M | Nov 13, 2026 |
| 5 | Renaissance Technologies LLC | 368,407 | +77,368 (+26.58%) | 2.88% | $0 M | Nov 12, 2026 |
| 6 | BIOS Capital Management, LP | 235,895 | -13,502 (-5.41%) | 1.85% | $0 M | Nov 13, 2026 |
| 7 | Two Sigma Investments, LP | 141,713 | New | 1.11% | $0 M | Nov 16, 2026 |
| 8 | UBS Group AG | 125,416 | +108,784 (+654.06%) | 0.98% | $0 M | Nov 10, 2026 |
| 9 | Geode Capital Management, LLC | 101,643 | -1,176 (-1.14%) | 0.80% | $0 M | Nov 6, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 49,950 | 0 (0.00%) | 0.39% | $0 M | Nov 13, 2026 |
| 11 | Westside Investment Management, Inc. | 47,850 | 0 (0.00%) | 0.37% | $0 M | Nov 2, 2026 |
| 12 | Susquehanna International Group, LLP | 39,155 | +25,082 (+178.23%) | 0.31% | $0 M | Nov 16, 2026 |
| 13 | HRT Financial LP | 30,307 | New | 0.24% | $0 M | Nov 13, 2026 |
| 14 | NewEdge Advisors, LLC | 26,699 | -350 (-1.29%) | 0.21% | $0 M | Nov 13, 2026 |
| 15 | DAVENPORT & Co LLC | 23,814 | 0 (0.00%) | 0.19% | $0 M | Oct 14, 2026 |
| 16 | State Street Corp | 23,652 | 0 (0.00%) | 0.18% | $0 M | Nov 12, 2026 |
| 17 | Horizon Kinetics Asset Management LLC | 22,746 | -2,418 (-9.61%) | 0.18% | $0 M | Nov 12, 2026 |
| 18 | BlackRock, Inc. | 22,230 | -120 (-0.54%) | 0.17% | $0 M | Nov 13, 2026 |
| 19 | Bank of New York Mellon Corp | 21,301 | 0 (0.00%) | 0.17% | $0 M | Nov 5, 2026 |
| 20 | Northern Trust Corp | 17,485 | 0 (0.00%) | 0.14% | $0 M | Nov 16, 2026 |
| 21 | Focus Partners Wealth | 15,432 | 0 (0.00%) | 0.12% | $0 M | Nov 12, 2026 |
| 22 | Squarepoint Ops LLC | 15,296 | New | 0.12% | $0 M | Nov 9, 2026 |
| 23 | XTX Topco Ltd | 15,244 | -2,171 (-12.47%) | 0.12% | $0 M | Nov 16, 2026 |
| 24 | Cetera Investment Advisers | 12,228 | 0 (0.00%) | 0.10% | $0 M | Nov 13, 2026 |
| 25 | Jane Street Group, LLC | 11,670 | New | 0.09% | $0 M | Nov 12, 2026 |
Show all 43: investors 26 to 43
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Farther Finance Advisors, LLC | 8,500 | -2,475 (-22.55%) | 0.07% | $0 M | Oct 8, 2026 |
| 27 | Nuveen, LLC | 4,102 | New | 0.03% | $0 M | Nov 10, 2026 |
| 28 | BFC Planning, Inc. | 3,760 | +500 (+15.34%) | 0.03% | $0 M | Nov 13, 2026 |
| 29 | Tower Research Capital LLC (TRC) | 2,982 | +1,820 (+156.63%) | 0.02% | $0 M | Nov 16, 2026 |
| 30 | Vanguard Global Advisers, LLC | 2,355 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 31 | Simplex Trading, LLC | 2,171 | -166 (-7.10%) | 0.02% | $0 M | Nov 4, 2026 |
| 32 | SBI Securities Co., Ltd. | 2,159 | 0 (0.00%) | 0.02% | $0 M | Oct 22, 2026 |
| 33 | Morgan Stanley | 602 | -37 (-5.79%) | 0.00% | $0 M | Nov 13, 2026 |
| 34 | IFP Advisors, Inc | 552 | New | 0.00% | $0 M | Oct 16, 2026 |
| 35 | Northwestern Mutual Wealth Management Co | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 36 | Colonial Trust Advisors | 400 | New | 0.00% | $0 M | Nov 10, 2026 |
| 37 | Entrust Financial LLC | 400 | -100 (-20.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 38 | Osaic Holdings, Inc. | 225 | +5 (+2.27%) | 0.00% | $0 M | Nov 12, 2026 |
| 39 | PlanVest Financial, Inc | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 40 | FMR LLC | 47 | New | 0.00% | $0 M | Nov 10, 2026 |
| 41 | Barclays PLC | 38 | +32 (+533.33%) | 0.00% | $0 M | Nov 6, 2026 |
| 42 | Group One Trading LLC | 23 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 43 | Key Financial Inc | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
Mutual funds holding Lantern Pharma Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 338,385 | $1 M | 2.6% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 81,101 | $0 M | 0.63% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 47,619 | $0 M | 0.37% | <0.01% | +3.8% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 15,273 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 11,259 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 6,838 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,832 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 1,924 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 643 | $0 M | <0.01% | <0.01% | −38% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Lantern Pharma Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lee Troy SchalopDirector | Buy | +48,544 | $2.060 | — | 48,544 | Form 4 |
| filed | D. Jeffrey KeyserDirector | Buy | +48,544 | $2.060 | $100 K | 94,303 | Form 4 |
| filed | BIOS Fund II QP, LP10% owner | Sellindirect | -7,206 | $3.090 | — | 189,117 | Form 4 |
| filed | BP Directors, LP10% owner | Sellindirect | -7,206 | $3.090 | $22 K | 189,117 | Form 4 |
| filed | BIOS Fund II QP, LP10% owner | Sellindirect | -12,319 | $3.090 | — | 323,335 | Form 4 |
| filed | BP Directors, LP10% owner | Sellindirect | -12,319 | $3.090 | $38 K | 323,335 | Form 4 |
| filed | BP Directors, LP10% owner | Sellindirect | -1,903 | $3.090 | $6 K | 49,957 | Form 4 |
| filed | BIOS Fund II QP, LP10% owner | Sellindirect | -1,903 | $3.090 | — | 49,957 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lantern Pharma Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2022 | Q4 2022 | $0M |
| Q3 2022 | Q3 2022 | $0M |
| Q2 2022 | Q2 2022 | $0M |
| Q1 2022 | Q1 2023 | $2.5M |
Trading halts
- 2025-09-16 12:25 UTC, code T3, resumed 12:45 UTC
Fails to deliver
- : 102 shares at $0.73
- : 32 shares at $0.77
- : 151 shares at $1.39
- : 495 shares at $1.55
- : 433 shares at $1.93
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lantern Pharma Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.8×Price to book 1.8× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-135.2%Free cash flow is -135.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.57 vs -1.93Diluted EPS -1.57 in fiscal 2025 against -1.93 the year before (report's currency).
- ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$6 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-123.5%-123.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.40 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Lantern Pharma Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | 11,514−28.6%— | 16,126+35.6%— | 11,894+38.3%— | 8,603+13.6%— | 7,571+237%— | 2,243r10—— | — | |
| General and administrative | 6,464+6.1%— | 6,091+1.8%— | 5,983+2.6%— | 5,830+16.1%— | 5,021+37.0%— | 3,665+148%— | 1,475—— | |
| Operating expenses | 17,978−19.1%— | 22,216+24.3%— | 17,878+23.9%— | 14,433+14.6%— | 12,592+113%— | 5,908+143%— | 2,428—— | |
| Operating income | −17,978—— | −22,216—— | −17,878—— | −14,433—— | −12,592—— | — | — | |
| Other non-operating income (expense) | 421−39.2%— | 693−39.8%— | 1,151—— | −32−120%— | 161—— | — | — | |
| Net income including minority interests | — | — | — | — | −12,363—— | −5,908r5,908−343%— | 2,428—— | |
| Minority interests' share of net income | — | — | — | — | 12,363+109%— | 5,908—— | — | |
| Net income attributable to shareholders | −17,119—— | −20,781—— | −15,962—— | −14,260—— | −12,363—— | −5,908—— | −2,428—— | |
| Earnings per share, basic | -1.57—— | -1.93—— | -1.47—— | -1.31—— | -1.13—— | -1.37—— | -1.23—— | |
| Earnings per share, diluted | -1.57—— | -1.93—— | -1.47—— | -1.31—— | -1.13—— | -1.37—— | -1.23—— | |
| Shares, weighted average (basic) | 11+1.3%— | 11−0.7%— | 11−0.1%— | 11−0.5%— | 11—— | — | — | |
| Shares, weighted average (diluted) | 11+1.3%— | 11−0.7%— | 11−0.1%— | 11−0.5%— | 11+153%— | 4.3+118%— | 2.0—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 4,423−41.1%40.1% | 7,511−65.8%29.4% | 21,938−41.0%50.3% | 37,202−27.8%63.2% | 51,524+168%69.7% | 19,229+1461%94.4% | 1,232—86.0% | |
| Short-term investments | 5,696−65.5%51.6% | 16,502−14.8%64.5% | 19,365+7.6%44.4% | 17,994−6.3%30.6% | 19,201—26.0% | — | — | |
| Other current assets | 684−44.6%6.2% | 1,235−39.4%4.8% | 2,039−31.7%4.7% | 2,985+50.0%5.1% | 1,991+97.6%2.7% | 1,008+127779%4.9% | 0.8—0.1% | |
| Current assets | 10,803−57.2%97.9% | 25,248−41.7%98.7% | 43,341−26.2%99.3% | 58,723−19.2%99.8% | 72,716+259%98.3% | 20,237+1542%99.4% | 1,233r1,232—86.1% | |
| Property, plant and equipment | 32−32.8%0.3% | 47−9.0%0.2% | 52+8.6%0.1% | 48+58.7%0.1% | 30+40.6%0.0% | 22+146%0.1% | 8.8—0.6% | |
| Right-of-use (leased) assets | 76−68.5%0.7% | 240+5.1%0.9% | 228+379%0.5% | 48−74.4%0.1% | 186—0.3% | — | — | |
| Total assets | 11,036−56.8%100% | 25,572−41.4%100% | 43,648−25.8%100% | 58,836−20.4%100% | 73,950+263%100% | 20,360+1321%100% | 1,433—100% | |
| Accounts payable | 4,423+6.8%40.1% | 4,140+65.3%16.2% | 2,505−8.7%5.7% | 2,745+26.3%4.7% | 2,174+294%2.9% | 552—2.7% | — | |
| Current liabilities | 4,502+3.9%40.8% | 4,331+61.7%16.9% | 2,678−4.3%6.1% | 2,798+20.3%4.8% | 2,326+321%3.1% | 552+12.9%2.7% | 489—34.2% | |
| Lease liabilities (non-current) | — | 53−14.1%0.2% | 61—0.1% | — | 53—0.1% | — | — | |
| Total liabilities | 4,502+2.7%40.8% | 4,384+60.0%17.1% | 2,740−2.1%6.3% | 2,798+17.6%4.8% | 2,379+260%3.2% | 661+35.1%3.2% | 489—34.2% | |
| Retained earnings | −93,145—−844% | −76,026—−297% | −55,244—−127% | −39,283—−66.8% | −25,023—−33.8% | −12,660—−62.2% | −6,752—−471% | |
| Shareholders' equity | 6,534−69.2%59.2% | 21,188−48.2%82.9% | 40,908−27.0%93.7% | 56,038−21.7%95.2% | 71,571+263%96.8% | 19,699+1988%96.8% | 943—65.8% | |
| Total equity | — | — | — | — | — | — | 943—65.8% | |
| Total liabilities and equity | 11,036−56.8%100% | 25,572−41.4%100% | 43,648−25.8%100% | 58,836−20.4%100% | 73,950+263%100% | 20,360+1321%100% | 1,433—100% | |
| Shares outstanding | 11+4.4%— | 11+0.6%— | 11−1.3%— | 11−2.1%— | 11+78.3%— | 6.2+214%— | 2.0—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 17−0.0%— | 17+18.2%— | 15+45.0%— | 10+49.1%— | 6.8+99.6%— | 3.4+108%— | 1.6—— | |
| Share-based compensation | 651−0.2%— | 652−35.9%— | 1,017r1,068−14.4%— | 1,188+23.5%— | 962—— | — | — | |
| Cash from operating activities | −15,677—— | −17,813—— | −14,347—— | −12,767—— | −10,592—— | −5,652—— | −2,128—— | |
| Capital expenditure | −1.7—— | −13—— | −19—— | −28—— | −15—— | — | — | |
| Cash from investing activities | 11,057+228%— | 3,369—— | −930−619%— | 179—— | −19,531—— | −16—— | −5.7—— | |
| Shares issued | 1,625—— | — | — | — | 69,000—— | — | — | |
| Shares bought back | — | — | −500—— | −2,482—— | −940—— | — | — | |
| Cash from financing activities | 1,498+2146%— | 67—— | −500—— | −2,182−103%— | 63,416+168%— | 23,665+710%— | 2,921—— | |
| Change in cash | −3,088—— | −14,427—— | −15,805—— | −14,781−144%— | 33,295+85.0%— | 17,997+2187%— | 787—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 8.7−39.3%— | 1.8−41.6%— | 1.7−47.2%— | 2.7*−35.7%— | 2.4−34.4%— | 3.1−21.1%— | 3.3−23.2%— | 4.3*+19.5%— | 3.7+68.2%— | 3.9—— | 4.3—— | 3.6*—— | 2.2—— | |
| General and administrative | 6.8+9.5%— | 1.7+8.4%— | 1.7+11.3%— | 1.5*−10.4%— | 1.9+30.8%— | 1.6+4.2%— | 1.5+1.9%— | 1.6*+24.7%— | 1.5+11.4%— | 1.5—— | 1.5—— | 1.3*—— | 1.3—— | |
| Operating expenses | 15−24.6%— | 3.5−24.6%— | 3.4−28.7%— | 4.2*−28.7%— | 4.3−16.0%— | 4.7−14.0%— | 4.8−16.7%— | 5.9*+20.9%— | 5.2+47.0%— | 5.4—— | 5.7—— | 4.9*—— | 3.5—— | |
| Operating income | −15—— | −3.5—— | −3.4—— | −4.2*—— | −4.3—— | −4.7—— | −4.8—— | −5.9*—— | −5.2—— | −5.4—— | −5.7—— | −4.9*—— | −3.5—— | |
| Other non-operating income (expense) | 0.2−72.3%— | 0.0−92.8%— | 0.0−61.2%— | 0.1*—— | 0.1−85.2%— | 0.2−20.8%— | 0.1−3.1%— | −0.1*−133%— | 0.5+317%— | 0.3—— | 0.1—— | 0.4*—— | 0.1—— | |
| Net income attributable to shareholders | −19—— | −7.1—— | −3.3—— | −4.1*—— | −4.2—— | −4.3—— | −4.5—— | −5.9*—— | −4.5—— | −5.0—— | −5.4—— | −4.2*—— | −3.2—— | |
| Earnings per share, basic | — | -0.57—— | -0.30—— | — | -0.39—— | -0.40—— | -0.42—— | — | -0.42—— | -0.46—— | -0.51—— | — | -0.29—— | |
| Earnings per share, diluted | — | -0.57—— | -0.30—— | — | -0.39—— | -0.40—— | -0.42—— | — | -0.42—— | -0.46—— | -0.51—— | — | -0.29—— | |
| Shares, weighted average (basic) | 12+15.2%— | 12+15.2%— | 11+4.3%— | — | 11+0.7%— | 11+0.2%— | 11+0.4%— | — | 11−0.9%— | 11—— | 11—— | — | 11—— | |
| Shares, weighted average (diluted) | 12+15.2%— | 12+15.2%— | 11+4.3%— | — | 11+0.7%— | 11+0.2%— | 11+0.4%— | — | 11−0.9%— | 11—— | 11—— | — | 11—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.7—77.4% | 6.7+9.9%77.4% | 4.9−22.9%68.1% | 4.4−41.1%40.1% | 8.4+3.5%61.6% | 6.1−53.3%34.8% | 6.4−65.3%30.2% | 7.5−65.8%29.4% | 8.1−68.3%26.7% | 13—36.5% | 18—46.2% | 22—50.3% | 26—53.5% | |
| Short-term investments | 0.7—8.1% | 0.7−92.9%8.1% | 1.4−89.5%19.5% | 5.7−65.5%51.6% | 4.0−80.1%29.2% | 9.8−51.5%56.5% | 13−33.3%63.3% | 17−14.8%64.5% | 20+3.1%65.9% | 20—57.0% | 20—50.3% | 19—44.4% | 19—40.5% | |
| Other current assets | 1.1—12.8% | 1.1−15.5%12.8% | 0.7−33.3%10.2% | 0.7−44.6%6.2% | 1.1−41.2%8.1% | 1.3−36.0%7.5% | 1.1−1.0%5.2% | 1.2−39.4%4.8% | 1.9−25.3%6.2% | 2.0—5.7% | 1.1—2.8% | 2.0—4.7% | 2.5—5.2% | |
| Current assets | 8.5—98.3% | 8.5−50.8%98.3% | 7.1−66.1%97.7% | 11−57.2%97.9% | 13−55.0%98.8% | 17−51.3%98.7% | 21−47.2%98.7% | 25−41.7%98.7% | 30−36.9%98.8% | 35—99.2% | 39—99.3% | 43—99.3% | 47—99.3% | |
| Property, plant and equipment | 0.0—0.3% | 0.0−38.6%0.3% | 0.0−36.3%0.4% | 0.0−32.8%0.3% | 0.0−26.5%0.3% | 0.0−21.4%0.2% | 0.0−12.4%0.2% | 0.0−9.0%0.2% | 0.0−4.1%0.2% | 0.1—0.1% | 0.1—0.1% | 0.1—0.1% | 0.1—0.1% | |
| Right-of-use (leased) assets | 0.0—0.4% | 0.0−73.3%0.4% | 0.1−70.4%0.8% | 0.1−68.5%0.7% | 0.1−67.5%0.7% | 0.1−32.8%0.8% | 0.2+2.7%0.9% | 0.2+5.1%0.9% | 0.3+6.7%0.9% | 0.2—0.6% | 0.2—0.5% | 0.2—0.5% | 0.3—0.6% | |
| Total assets | 8.6—100% | 8.6−50.6%100% | 7.2−65.8%100% | 11−56.8%100% | 14−55.0%100% | 17−51.0%100% | 21−46.9%100% | 26−41.4%100% | 30−36.6%100% | 36—100% | 40—100% | 44—100% | 48—100% | |
| Accounts payable | 4.3—49.8% | 4.3−9.9%49.8% | 3.7−9.9%51.5% | 4.4+6.8%40.1% | 3.9+15.9%29.0% | 4.8+7.1%27.3% | 4.1+9.3%19.6% | 4.1+65.3%16.2% | 3.4+63.2%11.2% | 4.4—12.5% | 3.8—9.5% | 2.5—5.7% | 2.1—4.4% | |
| Current liabilities | 4.3—50.2% | 4.3−11.5%50.2% | 3.8−11.9%52.3% | 4.5+3.9%40.8% | 4.0+12.2%29.6% | 4.9+6.2%28.0% | 4.3+8.4%20.3% | 4.3+61.7%16.9% | 3.6+59.8%11.9% | 4.6—12.9% | 4.0—9.9% | 2.7—6.1% | 2.3—4.7% | |
| Lease liabilities (non-current) | — | — | — | — | — | 0.0−75.3%0.1% | 0.0+115%0.2% | 0.1−14.1%0.2% | 0.1−11.8%0.3% | 0.1—0.2% | 0.0—0.0% | 0.1—0.1% | 0.1—0.2% | |
| Total liabilities | 12—137% | 12+141%137% | 3.8−12.6%52.3% | 4.5+2.7%40.8% | 4.0+9.3%29.6% | 4.9+5.2%28.1% | 4.3+8.8%20.5% | 4.4+60.0%17.1% | 3.7+56.6%12.2% | 4.7—13.1% | 4.0—10.0% | 2.7—6.3% | 2.4—4.9% | |
| Retained earnings | −104—−1204% | −104—−1204% | −96—−1336% | −93—−844% | −89—−654% | −85—−487% | −81—−382% | −76—−297% | −70—−232% | −66—−184% | −61—−153% | −55—−127% | −51—−107% | |
| Shareholders' equity | −3.2—−37.4% | −3.2−126%−37.4% | 3.4−79.5%47.7% | 6.5−69.2%59.2% | 9.6−64.0%70.4% | 13−59.5%71.9% | 17−53.1%79.5% | 21−48.2%82.9% | 27−41.4%87.8% | 31—86.9% | 36—90.0% | 41—93.7% | 45—95.1% | |
| Total liabilities and equity | 8.6—100% | 8.6−50.6%100% | 7.2−65.8%100% | 11−56.8%100% | 14−55.0%100% | 17−51.0%100% | 21−46.9%100% | 26−41.4%100% | 30−36.6%100% | 36—100% | 40—100% | 44—100% | 48—100% | |
| Shares outstanding | 13—— | 13+18.3%— | 11+4.4%— | 11+4.4%— | 11+2.4%— | 11+0.2%— | 11+0.2%— | 11+0.6%— | 11−0.8%— | 11—— | 11—— | 11—— | 11—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.0−12.4%— | 0.0*−16.7%— | 0.0−15.8%— | 0.0*−10.3%— | 0.0*−6.5%— | 0.0*+5.7%— | 0.0+12.6%— | 0.0*+15.1%— | 0.0*+18.3%— | 0.0*—— | 0.0—— | 0.0*—— | 0.0*—— | |
| Share-based compensation | — | — | — | 0.2*−2.8%— | 0.1−19.8%— | 0.2+19.7%— | 0.1+10.2%— | 0.2*+104%— | 0.2−6.1%— | 0.1—— | 0.1—— | 0.1r0.2*—— | 0.2—— | |
| Cash from operating activities | −14—— | −2.9*—— | −3.8—— | −2.8*—— | −4.6*—— | −3.9*—— | −4.4—— | −4.0*—— | −5.6*—— | −5.2*—— | −3.1—— | −3.4*—— | −3.6*—— | |
| Capital expenditure | — | — | — | −0.0*—— | −0.0*—— | 0*—— | −0.0—— | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—— | −0.0*—— | −0.0*—— | |
| Cash from investing activities | 9.2−16.4%— | 0.7*−80.7%— | 4.3+31.2%— | −1.7*−149%— | 5.9*+771%— | 3.6*—— | 3.2—— | 3.4*+1246%— | 0.7*+194%— | −0.2*—— | −0.6—— | 0.3*—— | 0.2*—— | |
| Shares issued | — | — | — | 0.7*—— | 0.0—— | — | — | — | — | — | — | — | — | |
| Cash from financing activities | — | — | — | 0.5*—— | — | — | — | 0*—— | 0.0*—— | 0*—— | 0.1—— | — | — | |
| Change in cash | 0.6—— | 1.7*—— | 0.5—— | −4.0*—— | 2.3*—— | −0.3*—— | −1.1—— | −0.6*—— | −4.9*—— | −5.4*—— | −3.6—— | −3.6*—— | −3.4*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Lantern Pharma Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Panna Sharma | $764 K | $779 K | $415 K | $71 |
| 2024Panna Sharma | $1.1 M | $1.0 M | $646 K | $75 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Lantern Pharma Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 2 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 1, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2019 | $2 M | No. 1 | $2 to $10 million | 5 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Lantern Pharma Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $78 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Digital Marketing ManagerPublic Relations Specialists | 1 | $78 K |
Where: Atlanta, GA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $78 K | 1 |
| FY2023 | 1 | 1 | $87 K | 1 |
| FY2022 | 1 | 1 | $52 K | 1 |
| FY2021 | 1 | 1 | $69 K | 1 |
| FY2020 | 5 | 5 | $79 K | 5 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Lantern Pharma, Inc.
How Lantern Pharma Inc. compares in Biotechnology
- Market cap$12 M · higher than 11% of 726
- Price / book1.8× · lower than 61% of 534
- FCF yield-135.2% · higher than 6% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lantern Pharma Inc.🇺🇸 | $12 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lantern Pharma Inc.? Verify and update this profile — free
Show Lantern Pharma Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.